Holen Sie sich die Stockscreener-App
13.62
2.48%
0.33
Handel nachbörslich:
13.35
-0.27
-1.98%
Schlusskurs vom Vortag:
$13.29
Offen:
$13.18
24-Stunden-Volumen:
603.75K
Relative Volume:
0.37
Marktkapitalisierung:
$874.73M
Einnahmen:
$161.10M
Nettoeinkommen (Verlust:
$-308.60M
KGV:
-2.9165
EPS:
-4.67
Netto-Cashflow:
$-259.90M
1W Leistung:
+13.22%
1M Leistung:
+12.01%
6M Leistung:
+73.72%
1J Leistung:
-25.21%
1-Tages-Spanne:
$13.14
$13.63
1-Wochen-Bereich:
$11.94
$13.63
52-Wochen-Spanne:
$5.90
$20.38
Arvinas Inc Stock (ARVN) Company Profile
Firmenname
Arvinas Inc
Sektor
Branche
Telefon
203-535-1456
Adresse
395 WINCHESTER AVE, NEW HAVEN, CT
Vergleichen Sie ARVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
13.62 | 853.54M | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2025-10-15 | Herabstufung | Goldman | Neutral → Sell |
| 2025-09-24 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-09-17 | Fortgesetzt | Barclays | Overweight |
| 2025-06-02 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2025-05-05 | Herabstufung | Truist | Buy → Hold |
| 2025-05-02 | Herabstufung | Jefferies | Buy → Hold |
| 2025-05-02 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-03-13 | Herabstufung | Goldman | Buy → Neutral |
| 2025-03-12 | Herabstufung | Wedbush | Outperform → Neutral |
| 2025-03-11 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-12-10 | Eingeleitet | BTIG Research | Buy |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-02-28 | Bestätigt | Oppenheimer | Outperform |
| 2024-02-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-02-01 | Eingeleitet | Goldman | Buy |
| 2023-12-19 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Hochstufung | Jefferies | Hold → Buy |
| 2023-11-20 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-10-23 | Hochstufung | Wedbush | Neutral → Outperform |
| 2023-06-26 | Fortgesetzt | Oppenheimer | Outperform |
| 2023-01-12 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Eingeleitet | Barclays | Overweight |
| 2022-06-21 | Eingeleitet | Jefferies | Hold |
| 2022-05-09 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-04-28 | Eingeleitet | Credit Suisse | Outperform |
| 2022-04-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Fortgesetzt | BMO Capital Markets | Outperform |
| 2022-02-10 | Eingeleitet | Wells Fargo | Overweight |
| 2022-01-19 | Eingeleitet | Goldman | Buy |
| 2021-12-07 | Eingeleitet | Cowen | Outperform |
| 2021-10-14 | Eingeleitet | SVB Leerink | Outperform |
| 2021-09-30 | Eingeleitet | Stifel | Buy |
| 2021-09-09 | Eingeleitet | BofA Securities | Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-21 | Eingeleitet | Truist | Buy |
| 2021-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-12-14 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Perform |
| 2019-12-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-11-25 | Eingeleitet | Guggenheim | Buy |
| 2019-10-24 | Hochstufung | Goldman | Neutral → Buy |
| 2019-09-25 | Eingeleitet | Wedbush | Outperform |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-08-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Herabstufung | Citigroup | Buy → Neutral |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-22 | Eingeleitet | Citigroup | Buy |
| 2018-10-22 | Eingeleitet | Goldman | Neutral |
| 2018-10-22 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Arvinas Inc Aktie (ARVN) Neueste Nachrichten
There Is A Reason Arvinas, Inc.'s (NASDAQ:ARVN) Price Is Undemanding - 富途牛牛
Gains Recap: Can Arvinas Inc reach all time highs this yearWeekly Market Summary & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Arvinas CEO John Houston to retire - MSN
New nanoparticle technology offers hope for hard-to-treat diseases - GlobeNewswire Inc.
Trading Systems Reacting to (ARVN) Volatility - Stock Traders Daily
Nordea Investment Management AB Grows Position in Arvinas, Inc. $ARVN - MarketBeat
Breakout Move: Can Arvinas Inc grow without external fundingJuly 2025 Spike Watch & Precise Buy Zone Identification - baoquankhu1.vn
Arvinas, Inc. $ARVN Stock Position Boosted by Campbell & CO Investment Adviser LLC - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Short Interest Down 27.9% in December - MarketBeat
Metastatic Prostate Cancer Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Merck, Arvinas Androgen Receptor, UNICANCER, Aragon Pharma, Mark Stein, Novartis - Barchart.com
Short Squeeze: Will Arvinas Inc stock gain from government policies2025 Institutional Moves & Precise Swing Trade Alerts - Bộ Nội Vụ
TAC to the future: Where induced proximity is pointing in 2026 - BioCentury
Here's Why We're Not Too Worried About Arvinas' (NASDAQ:ARVN) Cash Burn Situation - Yahoo Finance
Arvinas draws Wedbush downgrade after data for Pfizer-partnered cancer drug - MSN
Can Arvinas Inc. stock sustain institutional interestWeekly Earnings Recap & Real-Time Volume Surge Alerts - Улправда
Why Arvinas Inc. stock remains on buy lists2025 Winners & Losers & Weekly Top Performers Watchlists - Улправда
How Arvinas Inc. (ARVN) Affects Rotational Strategy Timing - Stock Traders Daily
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - sharewise.com
Is Arvinas Inc. stock positioned well for digital economyPortfolio Return Report & Capital Efficiency Focused Ideas - ulpravda.ru
Movement Recap: Why Arvinas Inc. stock remains resilient2025 AllTime Highs & Expert Verified Movement Alerts - Улправда
Will Arvinas Inc. stock remain a Wall Street favoriteJuly 2025 Patterns & AI Enhanced Market Trend Forecasts - Улправда
Arvinas Plunges 45% After Pfizer-Partnered Drug Disappoints - MSN
Sentiment Watch: Is Arvinas Inc. stock positioned for long term growthTrade Analysis Report & Risk Managed Investment Strategies - Улправда
Citigroup upgrades Arvinas (ARVN) - MSN
Citigroup Upgrades Arvinas (ARVN) - Nasdaq
Arvinas (NASDAQ:ARVN) Shares Gap UpTime to Buy? - MarketBeat
ARVN Stock: Citigroup Upgrades Arvinas to 'Buy' with 50% Target - GuruFocus
Arvinas (NASDAQ:ARVN) Shares Down 2.6%Should You Sell? - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Aug Patterns: Will Arvinas Inc stock remain a Wall Street favorite2025 Top Gainers & Safe Investment Capital Preservation Plans - moha.gov.vn
Arvinas, Inc. (ARVN) Stock Analysis: Navigating the Biotechnology Frontier with PROTAC Innovation - DirectorsTalk Interviews
Aug Closing: Is Arvinas Inc stock ready for breakoutEntry Point & Consistent Return Investment Signals - moha.gov.vn
(ARVN) and the Role of Price-Sensitive Allocations - Stock Traders Daily
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas announces preclinical data for ARV-393 - MSN
Will Arvinas Inc. stock deliver better than expected guidanceEarnings Recap Report & Reliable Volume Spike Alerts - Улправда
(ARVN) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Possible Bearish Signals With Arvinas Insiders Disposing Stock - simplywall.st
Barclays maintains Arvinas (ARVN) overweight recommendation - MSN
Barclays Raises Price Target for Arvinas (ARVN) to $18 | ARVN St - GuruFocus
Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN - MarketBeat
Armistice Capital LLC Invests $4.12 Million in Arvinas, Inc. $ARVN - MarketBeat
Arvinas Inc (NASDAQ:ARVN) Nasdaq Composite Biotech Innovation - Kalkine Media
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Velan Capital Investment Management LP Takes Position in Arvinas, Inc. $ARVN - MarketBeat
Diadema Partners LP Invests $710,000 in Arvinas, Inc. $ARVN - MarketBeat
Arvinas reveals promising preclinical data for ARV-393 - MSN
Arvinas Reveals Promising Preclinical Data for ARV-393 - TipRanks
Arvinas, Inc. Announces Preclinical Data for ARV-393 Combination - TradingView
22NW LP Acquires Shares of 413,533 Arvinas, Inc. $ARVN - MarketBeat
Arvinas (ARVN) Reveals Promising Preclinical Data for Cancer Tre - GuruFocus
Finanzdaten der Arvinas Inc-Aktie (ARVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):